Holdco Nuvo Group D.G Ltd. NUVOQ

0.00 0.00 NaN as of 25 Sep
Market cap
$2.1M
P/E
0.0×

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 58.44%

Capital & Financial Ratios

Market Cap 2.12
Revenue —
Net Income (33.65)
Free Cash Flow (14.96)
Net Debt 11.02
Current Ratio 0.05
Debt/Equity (0.17)
P/E ratio 0.00
P/S ratio 0.00
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth —
Next Y EPS Growth —
Next 5Y EPS Growth —
in millions of $

Dividends

Payout Ratio 0.00
Annual Dividend Rate —
Annual Dividend Yield —

Assets vs Liabilities

2020 2021 2022 2023
Cash — 1 0 1
Receivables — — — 0
Inventory — — 1 0
Other — 0 0 1
— 1 0 2
2020 2021 2022 2023
Payables — — 5 4
ST’ Debt — — 9 11
Other — 0 1 16
— 0 1 31
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — — —
Cash Flow — — 0.00%
Earnings — — 0.00%
Book Value — — 0.00%

Revenue

Mar Jun Sep Dec Year
’26 — — — — —
in millions of $ · fiscal quarters ending in the months shown

Operating Cash Flow

Mar Jun Sep Dec Year
’26 — — — — —
’23 0 0 0 (14) (15)
’22 0 0 1 (14) (13)
’22 — — — — (1)
’21 — — — (1) (14)
in millions of $ · fiscal quarters ending in the months shown

Free Cash Flow

Mar Jun Sep Dec Year
’26 — — — — —
’23 0 0 0 (14) (15)
’22 0 0 1 (14) (14)
’22 — — — — (1)
’21 — — — (1) (15)
in millions of $ · fiscal quarters ending in the months shown

EPS

Mar Jun Sep Dec Year
’26 — — — — —
’23 0.26 (0.24) (0.37) (1.88) (1.86)
’22 (0.05) (0.03) 0.14 (1.28) (1.21)
’22 — — — — 0.06
’21 — — 0.00 (0.01) (2.03)
fiscal quarters ending in the months shown

Target Price Range

Analyst price targets

Recommendation Rating

1Buy 2 3Hold 4 5Sell
2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
— — — — — — — — 9.72 9.41

Analyst estimates 2024–2026

Powerpack
Low Price
— — — — — — — — 10.71 11.66
High Price
— — — — — — — 3 3 59
Employees
— — — — — — — 0 0 0
Revenue/Emp
— — — — — — — — — 0
Revenue
— — — — — — — — — (8.52%)
Gross Margin
— — — — — — — (34) (20) (35)
EBT
— — — — — — — 0.00% 0.00% (19,712.50%)
EBT Margin
— — — 0 — — — (35) (21) (34)
Net Income
— — — — — — — 0 0 0
Depreciation
— — — — — — — 0.00 0.00 0.01
Revenue/Sh
— — — — — — — (2.03) (1.21) (1.86)
Earnings/Sh
— — — — — — — (0.85) (0.79) (0.83)
Cash Flow/Sh
— — — — — — — (0.01) (0.01) 0.00
Capex/Sh
— — — — — — — (0.86) (0.81) (0.83)
Free CF/Sh
— — — — — — — (0.51) (2.27) (3.74)
Book Value/Sh
— — — — — — — 17 17 18
Shares
— — — — — — — — — 0.00
PE Ratio
— — — — — — — — — 0.00
PS Ratio
— — — — — — — — — 0.00
PB Ratio
— — — — — — — — — 0.00
EV/Sales
— — — — — — — — — (13.73)
EV/FCF
— — — — — — — (14) (13) (15)
Op' Cash Flow
— — — — — — — 0 0 0
Capex
— — — — — — — (15) (14) (15)
FCF
— — — — — — — 1 (39) (29)
Working Cap'
— — — — — — — — 9 12
Total Debt
— — — — — — — (1) 8 11
Net Debt
— — — — — — — (9) (39) (67)
Sh' Equity
— — — — — — — (13.15%) (15.36%) (930.47%)
ROA
— — — — — — — 0.00% 0.00% 0.00%
ROIC
— — — — — — — (28.67%) (19.42%) 63.38%
ROE
predictions in italic, sparklines do not include predictions

All 10 years →

Fiscal years to Dec 2023

Holdco Nuvo Group D.G Ltd. peers in Medical Devices

All 149 Medical Devices stocks →

Holdco Nuvo Group D.G Ltd. (NUVOQ) key facts

  • Holdco Nuvo Group D.G Ltd. (NUVOQ) is a Medical Devices company in the Healthcare sector.
  • Holdco Nuvo Group D.G Ltd.’s revenue for fiscal 2023 (year ended December 2023) was $176,000.00.
  • Return on equity was 63.4% and debt-to-equity -0.17.

Source: company filings (standardised) and stockrow calculations.

Holdco Nuvo Group D.G Ltd. (NUVOQ) Latest News

News by impact score

Fine-tune

4 Sep

4

US Bankruptcy Court imposes restrictions on trading in equity interests in Holdco Nuvo Group D.G Ltd. and affiliates. The court order imposing restrictions on trading in equity interests is a significant event that could fundamentally alter the company's trajectory and investor sentiment.

9 May

4

Nuvo Group appoints Adriana Machado to its board of directors to enhance its mission of improving pregnancy care through remote monitoring technology. The addition of a seasoned health and impact expert like Adriana Machado is expected to significantly strengthen Nuvo's strategic direction and market impact.

1 May

4

Nuvo Group Ltd. completes business combination with LAMF Global Ventures Corp. to become a public company, trading on NASDAQ under ticker symbol NUVO. The completion of the business combination and access to capital markets are expected to significantly impact Nuvo's future growth and market performance.

12 Apr

3

LAMF Global Ventures Corp. I extends deadline for business combination. The extension of the deadline for the business combination may moderately influence the company's financial performance and competitive positioning.

2 Apr

4

LAMF Global Ventures Corp. I shareholders approve business combination with Nuvo Group Ltd. The approved business combination is expected to significantly impact LGVC's future market performance and strategic direction.

26 Mar

3

LAMF Global Ventures Corp. I intends to adjourn extraordinary general meeting of shareholders until April 1, 2024. The adjournment of the meeting may moderately influence the company's future business combination with Nuvo Group Ltd.

12 Feb

3

LAMF Global Ventures Corp. I extends deadline for business combination. The extension of the deadline may moderately influence the company's future performance and market positioning.

8 Jan

3

LAMF Global Ventures Corp. I extends deadline for business combination to February 16, 2024. The extension of the deadline may moderately influence the company's future performance.

18 Aug

4

Nuvo Group Ltd. to merge with LAMF Global Ventures Corp. I, creating a public company on Nasdaq with a focus on pregnancy care technology. The merger with Nuvo Group Ltd. is a significant strategic move that is expected to have a profound influence on LGVC's future and market performance.

stockrow.com/NUVOQ · Data as of Dec 31, 2023 · For information only; not investment advice. · © 2026 stockrow.com